Trial Profile
A Phase II Study of Erlotinib in Patients with Polycythaemia Vera and Essential Thrombocythemia.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Nov 2013
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Essential thrombocythaemia; Polycythaemia vera
- Focus Pharmacogenomic; Therapeutic Use
- 09 Aug 2011 New trial record